Greater Apathy Associated With Selective Serotonin Reuptake Inhibitor Use in Parkinson's Disease

Area of Science:

• Neuroscience
• Psychiatry
• Movement Disorders

Background:

• Apathy is a common motivational deficit in Parkinson's disease (PD), frequently misdiagnosed as depression.
• Selective serotonin reuptake inhibitors (SSRIs) have been associated with increased apathy in other populations.
• Serotonin's potential to downregulate dopaminergic systems in PD warrants investigation into SSRI use and apathy.

Purpose of the Study:

• To investigate the relationship between selective serotonin reuptake inhibitor (SSRI) use and apathy in individuals with Parkinson's disease (PD).
• To determine if SSRIs are uniquely associated with apathy compared to other antidepressant classes in PD patients.

Main Methods:

• A convenience sample of 400 individuals with PD was assessed.
• Collected data included medication use, mood/motivation scales (Beck Depression Inventory-II, Apathy Scale), and clinical information.
• Antidepressant medications were categorized by mechanism of action for analysis.

Main Results:

• 26% of the Parkinson's disease (PD) sample were prescribed SSRIs.
• Hierarchical regression analysis indicated SSRIs were significantly associated with higher apathy scores (β = .1, P = .02).
• Lower education, poorer cognition, and higher depression scores also predicted increased apathy.

Conclusions:

• SSRI use, unlike other antidepressants, is significantly associated with greater apathy in individuals with Parkinson's disease (PD).
• The findings emphasize considering apathy when prescribing antidepressants to PD patients due to serotonin-dopamine interactions.
• Switching from SSRIs to alternative antidepressants may be a potential therapeutic strategy for apathy in PD, requiring further research.